Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,547 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03437941 | Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 39 | Corcept TherapeuticsINDUSTRY | 2 | May 15, 2026 | clinicaltrials |
| NCT03910660 | A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. | completed | Phase 1 / Phase 2 | 98 | BioXcel Therapeutics IncINDUSTRY | 2 | May 15, 2026 |
| clinicaltrials |
| NCT07244341 | A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) | recruiting | Phase 1 | 60 | Daiichi SankyoINDUSTRY | 4 | May 15, 2026 | clinicaltrials |
| NCT07564102 | dMD-002 Pilot Study in Patients With Cavernous Nerve Injury Following Radical Prostatectomy | not yet recruiting | Phase 1 / Phase 2 | 30 | Mochida Medical USA, Inc.INDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT05413850 | Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection | recruiting | Phase 1 / Phase 2 | 82 | Blue Earth Therapeutics LtdINDUSTRY | 5 | May 14, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07583160 | YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer(YS247) | enrolling by invitation | Phase 1 | 18 | Changhai HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT04846478 | Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC | active not recruiting | Phase 1 | 35 | Dana-Farber Cancer InstituteOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT06879041 | A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 136 | AstraZenecaINDUSTRY | 3 | May 12, 2026 | clinicaltrials |
| NCT04486755 | Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048) | active not recruiting | Phase 1 | 18 | University of Maryland, BaltimoreOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT07414940 | ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium(ACT-RESoLUTE) | recruiting | Phase 1 / Phase 2 | 60 | University College, LondonOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03123978 | Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 6 | University of California, DavisOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04868604 | 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)(SECuRE) | recruiting | Phase 1 / Phase 2 | 54 | Clarity Pharmaceuticals LtdINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT03217747 | Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies | active not recruiting | Phase 1 / Phase 2 | 173 | M.D. Anderson Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05125016 | A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 228 | Regeneron PharmaceuticalsINDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT06616155 | Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 20 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03067051 | Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System | recruiting | Phase 1 / Phase 2 | 66 | SpectraCure ABINDUSTRY | 4 | May 1, 2026 | clinicaltrials |
| NCT04194554 | A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer(ASCLEPIuS) | active not recruiting | Phase 1 / Phase 2 | 102 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT06807359 | Photodynamic Therapy of Primary Localized Prostate Cancer With the SpectraCure P18 System | recruiting | Phase 1 / Phase 2 | 43 | SpectraCure ABINDUSTRY | 2 | May 1, 2026 | clinicaltrials |
| NCT04597411 | Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer | active not recruiting | Phase 1 | 101 | EndocyteINDUSTRY | 2 | Apr 30, 2026 | clinicaltrials |
| NCT03218826 | PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07117760 | Prospective Clinical Trial of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 16 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06104449 | A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005) | completed | Phase 1 | 7 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Apr 27, 2026 | clinicaltrials |
| NCT02555189 | Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression | terminated | Phase 1 / Phase 2 | 52 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT04946370 | Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 52 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07407283 | A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer | recruiting | Phase 1 / Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT07219147 | 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05022849 | A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants | completed | Phase 1 | 15 | Janssen Research & Development, LLCINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07537010 | 3D1015 Injection for Patients With mCRPC | recruiting | Phase 1 | 8 | Chunjing YuOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06615752 | Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients | recruiting | Phase 1 / Phase 2 | 99 | Charles Drew University of Medicine and ScienceOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07236112 | Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer | active not recruiting | Phase 1 | 6 | C Ray TherapeuticsINDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06044857 | PSMA PET Response Guided SabR in High Risk Pca | recruiting | Phase 1 | 20 | University of Texas Southwestern Medical CenterOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT06190899 | Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 54 | Celcuity IncINDUSTRY | 4 | Apr 13, 2026 | clinicaltrials |
| NCT07192120 | A Study of MHB048C in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Apr 9, 2026 | clinicaltrials |
| NCT06303713 | LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer | active not recruiting | Phase 1 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT07214961 | Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)(ARTISAN) | active not recruiting | Phase 1 | 80 | ARTBIO Inc.INDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04147806 | A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer(PROSINT) | active not recruiting | Phase 1 | 31 | Albert Einstein College of MedicineOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06451497 | This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 100 | Zumutor Biologics Inc.INDUSTRY | 1 | Apr 2, 2026 | clinicaltrials |
| NCT07259213 | A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC(RAD402) | recruiting | Phase 1 / Phase 2 | 73 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT03674814 | Study of Drug 1 (Enzalutamide) Plus Drug 2 (Relacorilant) for Patients With Prostate Cancer | completed | Phase 1 | 42 | University of ChicagoOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT04853498 | A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3720 Tablets | terminated | Phase 1 | 192 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Mar 31, 2026 | clinicaltrials |
| NCT06193486 | Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC | recruiting | Phase 1 | 30 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | active not recruiting | Phase 1 | 499 | Agenus Inc.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT06395519 | A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies(ERADIC8) | recruiting | Phase 1 / Phase 2 | 120 | 858 Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06705686 | Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer(PHAROS) | recruiting | Phase 1 | 40 | TechnoGenesys, Inc.INDUSTRY | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06136598 | A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001) | completed | Phase 1 | 14 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05245006 | PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer | active not recruiting | Phase 1 | 30 | Robert Flavell, MD, PhDOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT05888532 | 64Cu-GRIP B in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 91 | Rahul AggarwalOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2026source: clinicaltrials